Teva Pharmaceutical Industries Limited (TEVA) Shares Bought by GFS Advisors LLC

Investors say Teva, which faces pricing pressure in its core generics business and recently lost patent protection on its key branded drug Copaxone for multiple sclerosis, must choose a new CEO with extensive pharmaceutical experience. Sharkey Howes & Javer increased its position in Teva Pharmaceutical Industries Limited by 21.7% in the second quarter. The company is set at a mean analysts' recommendation of 2.20. The third largest holder is Barrow Hanley Mewhinney & Strauss Llc, which now holds $1.04 billion worth of this stock and that ownership represents almost 3% of its market capitalization. For the next quarter the company has anticipated average revenues of $5.87B, according to the sentiments of 13 analysts. Washington Trust Bank raised its position in Teva Pharmaceutical Industries Limited by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company's stock worth $103,000 after buying an additional 58 shares during the period. Kistler Tiffany Companies LLC raised its position in Teva Pharmaceutical Industries Limited by 14.1% in the third quarter. The company reported $1.38 EPS for the quarter, beating the Zacks' consensus estimate of $1.36 by $0.02.

"This is a critical time for Teva, and we are here to fix what is not working", he added during the company's call with investors Monday.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) stock ended Friday session in the red zone in a volatile trading.

The stock exchanged hands 13.82M shares versus average trading capacity of 12.31M shares, while its shares' total market worth is $32.73B along with 1.01B outstanding shares. The company's 50-day moving average is $34.51 and its 200 day moving average is $42.93.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) reached 6.58% versus a 1-year low price of $31.9.

More news: Fake News Firestorm Hits French Presidential Election

For the quarter, Teva reported a loss of $973 million, or $1.10 a share, compared with a profit of $500 million, or 55 cents a share, the same quarter the year before. Teva Pharmaceutical Industries Limited had a net margin of 8.81% and a return on equity of 16.75%. The business's revenue was up 33.0% on a year-over-year basis. For the current quarter the stock has lowest EPS estimates of $1.17 and high estimate of $1.44.

Teva earned $1.38 per share excluding one-time items in the quarter, up from $1.28. Shareholders of record on Thursday, March 2nd will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 4.00%. Teva Pharmaceutical Industries Limited's payout ratio is 67.44%. If you are reading this news story on another website, it was copied illegally and reposted in violation of global copyright and trademark laws. The correct version of this news story can be read at [[permalink]]. Morgan Stanley Downgrades Teva Pharmaceutical Industries Limited (NYSE:TEVA) to Equal-Weight with a price target of $42. Citigroup Inc. reaffirmed a "buy" rating and set a $47.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, February 7th.

"Teva Pharmaceutical Industries Limited (TEVA) Shares Bought by GFS Advisors LLC" was originally published by Community Financial News and is owned by of Community Financial News. Finally, Mizuho reduced their target price on Teva Pharmaceutical Industries Limited from $45.00 to $40.00 and set a "neutral" rating for the company in a report on Wednesday, November 16th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The relative price strength of Teva Pharmaceutical Industries Limited has a negative value of -32.26 compared to overall market performance. Teva Pharmaceutical Industries Ltd (ADR) was Downgraded by Wells Fargo to Market Perform on Jan 9, 2017.

Research-and-development costs jumped 53% to $684 million, with expenses rising for both generics and specialty as well as from an upfront payment of $160 million to Celltrion to commercialize two biosimilar drugs.

Edition: